Related Experiment Video

Updated: Mar 8, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

Bin-Chi Liao1,2,3, Chia-Chi Lin1,4, James Chih-Hsin Yang5,6,7,8

  • 1Department of Oncology, National Taiwan University Hospital, 7, Chung-Shan South Road, Taipei, Taiwan.

Current Oncology Reports
|February 1, 2017
PubMed

Insights

Afatinib offers survival benefits as a first-line treatment for advanced EGFR mutation-positive non-small cell lung cancer (NSCLC). It also shows effectiveness in second-line settings and combination therapies for NSCLC patients.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Research

Background:

  • Afatinib is a second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.
  • It is approved globally for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations.

Purpose of the Study:

  • To review recent clinical developments and therapeutic benefits of afatinib in lung cancer treatment.
  • To highlight emerging data on afatinib's efficacy in various NSCLC patient subgroups and treatment settings.

Main Methods:

  • Review of recent clinical data and Phase III studies involving afatinib.
  • Analysis of treatment outcomes in patients with EGFR mutations, lung squamous cell carcinoma, and central nervous system metastasis.
  • Investigation of afatinib in combination with chemotherapy and for HER2-mutated lung cancer.

Main Results:

  • First-line afatinib demonstrates an overall survival benefit in advanced EGFR del19-positive NSCLC.
  • Afatinib is effective as a second-line treatment for advanced lung squamous cell carcinoma.
  • Continuing afatinib with chemotherapy shows benefit in advanced NSCLC post-progression; benefits also seen in CNS metastasis and HER2 mutation cases.

Conclusions:

  • Afatinib provides significant therapeutic benefits across various advanced NSCLC scenarios, including first-line, second-line, and specific mutations.
  • Ongoing research is exploring afatinib-based combination therapies to further enhance treatment outcomes in lung cancer.
Keywords:
AfatinibCentral nervous system metastasisEGFR mutationHER2 mutationNon-small cell lung cancerSquamous cell carcinoma

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
519
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
609